Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness

Simply Wall St.

Jun 02

AdvertisementRecent Stock Performance and Business Context Corvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2640502946"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640502946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640502946?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-02 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640502946","market":"us","top_or_hot":-1,"title":"Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent Stock Performance and Business Context Corvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Corvus Pharmaceuticals (CRVS) Valuation After Strong One Year Gains And Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-02 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent Stock Performance and Business Context Corvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong","article_id":"2640502946","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crvs/corvus-pharmaceuticals/news/assessing-corvus-pharmaceuticals-crvs-valuation-after-strong","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2640502946","pubTimestamp":1780406530,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent Stock Performance and Business Context\nCorvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past day and 4.2% over the past week.\nThose short term moves sit alongside a decline of 21.9% over the past month and 31.1% over the past 3 months, while the stock shows a year to date gain of 65% and a 1 year total return close to 200%.\nSee our latest analysis for Corvus Pharmaceuticals.\nAt a share price of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc.","BK4568":"美国抗疫概念","BK4139":"生物科技"},"translate_title":"在一年强劲上涨和近期股价疲软后评估Corvus Pharmaceuticals(CRVS)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1.5},"content_text":"AdvertisementRecent Stock Performance and Business Context Corvus Pharmaceuticals (CRVS) has drawn investor attention after a period of sharp share price swings, with the stock down 2.7% over the past day and 4.2% over the past week. Those short term moves sit alongside a decline of 21.9% over the past month and 31.1% over the past 3 months, while the stock shows a year to date gain of 65% and a 1 year total return close to 200%. See our latest analysis for Corvus Pharmaceuticals. At a share price of $12.08, Corvus Pharmaceuticals shows fading short term momentum after recent declines in share price returns, despite a very large 1 year total shareholder return and strong multi year total shareholder returns. If this kind of high risk biotech story interests you, it can be useful to compare it with other healthcare stocks using our screener of 40 healthcare AI stocks With Corvus trading at $12.08 against an analyst price target of $33.33, the stock appears to trade at a steep discount on paper. The key question is whether this represents a genuine opportunity or whether the market is already factoring in future growth. Most Popular Narrative: 65.5% Undervalued At a last close of $12.08 against a narrative fair value of $35, Corvus Pharmaceuticals is framed as heavily discounted, with that gap hinging on ambitious long range projections.  Corvus reports cash, cash equivalents and marketable securities of US$65.7 million and currently expects this to fund operations into the fourth quarter of 2026. This provides a runway to reach key readouts like the Cohort 4 extension data, Phase II atopic dermatitis progress and interim PTCL data, events that could influence future revenue expectations, R&D efficiency and ultimately earnings power.  Read the complete narrative. Curious what has to happen between now and those trial readouts to support that higher fair value number? The widely followed narrative leans on a rapid build in revenue, a clear path to healthier margins and an earnings multiple that assumes meaningful progress in the pipeline. The full breakdown explains how these moving parts fit together. Result: Fair Value of $35 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on soquelitinib delivering clean data in key trials and on Corvus avoiding heavy dilution as it funds multiple studies through 2026. Find out about the key risks to this Corvus Pharmaceuticals narrative. Another View: What The P/B Ratio Is Saying While the narrative fair value points to Corvus Pharmaceuticals looking 65.5% undervalued at $35, the current P/B ratio of 4.2x tells a different story when compared with the US Biotechs industry at 2.6x and peers at 3.5x. That premium suggests higher valuation risk if the ambitious growth path does not materialise in full. How comfortable are you with paying above peer and industry levels today? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:CRVS P/B Ratio as at Jun 2026Next Steps With sentiment split between strong past returns and clear valuation questions, now is a good time to look under the hood yourself and act quickly while forming your own view by weighing the 1 key reward and 3 important warning signs Looking for more investment ideas? If Corvus has caught your attention, do not stop there. A broader watchlist can help you spot opportunities and manage risk across different types of stocks.  Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals using the 47 high quality undervalued stocks. Prioritise resilience by focusing on businesses with strong finances and less fragile balance sheets through the 62 resilient stocks with low risk scores. Hunt for underfollowed opportunities with solid fundamentals by checking the screener containing 22 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}